A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.

Dada T, Salha O, Baillie HS, Sharma V

Human reproduction (Oxford, England)1 Feb 1999Cited by 25 (Europe PMC)

PMID10099965DOI10.1093/humrep/14.2.288PepBankPUB-10099965

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF patients, nafarelin produced greater oestradiol suppression than buserelin at day 15, 72% versus 54% (P < 0.05).
In plain wordsNafarelin suppressed oestradiol more than buserelin at day 15.
Peptide
Nafarelin
Outcome
IncreaseOestradiol suppression at day 15
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Oestradiol suppression
72%
nafarelin
Oestradiol suppression
54%
buserelin
Source sentences
Summary
We found that on day 15 of administration there was a significant difference in the suppression of oestradiol from initial concentrations, when patients on buserelin were compared with patients on nafarelin or leuprorelin (54 versus 72 and 65%; P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996501
02HumanRandomized controlled trialEfficacy outcome
In IVF patients, satisfactory suppression occurred in 90% with nafarelin versus 80% with buserelin at day 15 (P < 0.05).
In plain wordsMore patients achieved satisfactory suppression with nafarelin than buserelin at day 15.
Peptide
Nafarelin
Outcome
IncreaseSatisfactory suppression at day 15
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Satisfactorily suppressed patients
90%
nafarelin, day 15
Satisfactorily suppressed patients
80%
buserelin, day 15
Source sentences
Summary
and also in the number of patients satisfactorily suppressed, (80 versus 90 and 90%; P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996502
03HumanRandomized controlled trialEfficacy outcome
In IVF patients, hormonal suppression with nafarelin did not differ from buserelin by day 21.
In plain wordsNafarelin and buserelin did not differ in hormonal suppression by day 21.
Peptide
Nafarelin
Outcome
No significant changeHormonal suppression at day 21
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
though there were no differences between the analogues by day 21.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996503
04HumanRandomized controlled trialEfficacy outcome
In IVF patients, hormonal suppression with nafarelin did not differ from leuprorelin by day 21.
In plain wordsNafarelin and leuprorelin did not differ in hormonal suppression by day 21.
Peptide
Nafarelin
Outcome
No significant changeHormonal suppression at day 21
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
though there were no differences between the analogues by day 21.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996504
05HumanRandomized controlled trialEfficacy outcome
In IVF patients, nafarelin and buserelin did not differ in hormonal suppression during stimulation or implantation, pregnancy, and miscarriage rates.
In plain wordsNafarelin and buserelin did not differ in hormonal suppression during stimulation or implantation, pregnancy, and miscarriage rates.
Peptide
Nafarelin
Outcome
No significant changeHormonal suppression and IVF outcomes during stimulation
Study
n: not reported in source
Comparator
Buserelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Similarly there was no difference in hormonal suppression during the stimulation phase or in implantation, pregnancy or miscarriage rates in comparing the three agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996505
06HumanRandomized controlled trialEfficacy outcome
In IVF patients, nafarelin and leuprorelin did not differ in hormonal suppression during stimulation or implantation, pregnancy, and miscarriage rates.
In plain wordsNafarelin and leuprorelin did not differ in hormonal suppression during stimulation or implantation, pregnancy, and miscarriage rates.
Peptide
Nafarelin
Outcome
No significant changeHormonal suppression and IVF outcomes during stimulation
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Similarly there was no difference in hormonal suppression during the stimulation phase or in implantation, pregnancy or miscarriage rates in comparing the three agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996506
07HumanRandomized controlled trialEfficacy outcome
In IVF patients, oestradiol suppression at day 15 was 72% with nafarelin and 65% with leuprorelin.
In plain wordsOestradiol suppression at day 15 was numerically greater with nafarelin than leuprorelin.
Peptide
Nafarelin
Outcome
IncreaseOestradiol suppression at day 15 versus leuprorelin
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Oestradiol suppression
72%
nafarelin
Oestradiol suppression
65%
leuprorelin
Source sentences
Summary
We found that on day 15 of administration there was a significant difference in the suppression of oestradiol from initial concentrations, when patients on buserelin were compared with patients on nafarelin or leuprorelin (54 versus 72 and 65%; P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996507
08HumanRandomized controlled trialEfficacy outcome
In IVF patients, satisfactory suppression at day 15 occurred in 90% with nafarelin and 90% with leuprorelin.
In plain wordsSatisfactory suppression at day 15 occurred in the same proportion with nafarelin and leuprorelin.
Peptide
Nafarelin
Outcome
No significant changeSatisfactory suppression at day 15 versus leuprorelin
Study
n: not reported in source
Comparator
Leuprorelin
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Satisfactory suppression
90%
nafarelin
Satisfactory suppression
90%
leuprorelin
Source sentences
Summary
and also in the number of patients satisfactorily suppressed, (80 versus 90 and 90%; P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome.
Report a problemFND-1009996508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.